Drug intelligence / Profile preview

IVT Klebsiella

Development stage: Preclinical
Lead developer: Inventprise
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

IVT Klebsiella is a vaccine candidate under development by Inventprise targeting infections caused by *Klebsiella pneumoniae*. The vaccine leverages Inventprise’s proprietary conjugation technology platform and is designed to reduce neonatal mortality from bacterial infections due to *K. pneumoniae*. If effective, it may also help decrease antibiotic use in patients with chronic obstructive pulmonary disease (COPD) and contribute to reducing the emergence of antimicrobial resistance. The primary mechanism involves inducing an immune response against *Klebsiella pneumoniae* through vaccination, thereby preventing infection or reducing its severity[8].

Brand names: IVT Klebsiella
Other names: IVT-Klebsiella

Targets

O-antigen (Salmonella Typhimurium O-antigen polysaccharide)

Beyond the preview

Go deeper on IVT Klebsiella.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVT Klebsiella.

Explore the full profile